Nautilus Biotechnology Inc expected to post a loss of 13 cents a share - Earnings Preview
Nautilus Biotechnology Inc <NAUT.OQ> expected to post a loss of 13 cents a share - Earnings Preview
Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to show no change in quarterly revenue when it reports results on July 28 for the period ending June 30 2026
LSEG's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $4.00, about 126% above its last closing price of $1.77
This summary was machine generated July 24 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Nautilus Biotechnology
See all newsNautilus Biotechnology, Inc. expected to post a loss of 14 cents a share - Earnings Preview
Brief: Nautilus Biotechnology May Offer Up To $300 Million Of Securities - SEC Filing
Nautilus Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Nautilus Biotechnology posts first revenue, Q2 net loss narrows
Brief: Nautilus Biotechnology Q2 EPS USD -0.11